adc

BIO Asia 2024 in Taiwan featured breakthroughs in biotech and antibodies. Biointron shares key takeaways that define trends in global biologics and innovation.

Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.

​A recent editorial by researchers at Yale University School of Medicine describes how we are entering the golden age for antibody-drug conjugates (ADCs) in gynecologic cancer, which includes difficult to treat tumors such as uterine carcinosarcomas and platinum-resistant ovarian cancer.

Antibody-drug conjugates unite antibody precision with cytotoxic potency. Biointron explains how ADCs deliver targeted therapies that revolutionize cancer treatment.

Immunostimulatory ADCs (iADCs), also known as immune-stimulating antibody conjugates (iSACs), arean advanced form of targeted cancer therapy. They not only activate innate immunity but also stimulate adaptive immunity, providing a dual therapeutic effect to eliminate tumor cells. They combine

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.

ADCs rely on diverse payloads. Biointron explores cytotoxic drugs and novel mechanisms that expand antibody-drug conjugate applications in oncology and beyond.

Multi-payload ADCs bring new strength to cancer therapy. Biointron explains how combining payloads boosts potency, reduces resistance, and improves patient outcomes.

AET Europe 2024 in London spotlighted antibody innovation. Biointron shares event takeaways on discovery, engineering, and development shaping the therapeutic pipeline.

Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and

Antibody-antibiotic conjugates fight resistant bacteria with precision. Biointron highlights how AACs combine antibody targeting with antibiotic power for infections.

ADCs for ES-SCLC. Image credit: DOI: 10.3390/genes15060701Extensive-stage small-cell lung cancer (ES-SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Antibody drugs, especially immune checkpoint inhibitors, have emerged as a promising treatme

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.